{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:51:06Z","timestamp":1758635466831},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.transproceed.2018.02.110","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T15:33:04Z","timestamp":1521387184000},"page":"1720-1725","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes of Prolonged Treatment With Intravenous Immunoglobulin Infusions for Acute Antibody-mediated Rejection in Kidney Transplant Recipients"],"prefix":"10.1016","volume":"50","author":[{"given":"A.","family":"Bujnowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Michon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Konopelski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Hryniewiecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Jalbrzykowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Perkowska-Ptasinska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Cieciura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Zagozdzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Paczek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ciszek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2018.02.110_bib1","first-page":"CD004756","article-title":"Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients","volume":"7","author":"Webster","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.transproceed.2018.02.110_bib2","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1016\/j.transproceed.2012.02.037","article-title":"The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature","volume":"44","author":"Tzvetanov","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.02.110_bib3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/MOT.0000000000000249","article-title":"Eculizumab use in kidney transplantation","volume":"20","author":"Johnson","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.transproceed.2018.02.110_bib4","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.transproceed.2015.06.029","article-title":"Eculizumab for treatment of refractory antibody-mediated rejection in kidney transplant patients: a single-center experience","volume":"47","author":"Yelken","year":"2015","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2018.02.110_bib5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/TP.0000000000000959","article-title":"The challenge of aute antibody-mediated rejection in kidney transplantation","volume":"100","author":"Chehade","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.02.110_bib6","first-page":"255","article-title":"14th International HLA and immunogenetics workshop prospective chronic rejection project: a three-year follow-up analysis","author":"Ozawa","year":"2007","journal-title":"Clin Transpl"},{"key":"10.1016\/j.transproceed.2018.02.110_bib7","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/TP.0b013e3181cbac02","article-title":"Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection","volume":"89","author":"Everly","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.02.110_bib8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/TP.0000000000000958","article-title":"One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial","volume":"100","author":"Sautenet","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.02.110_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaci.2010.10.030","article-title":"The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders","volume":"127","author":"Ballow","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.transproceed.2018.02.110_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ajt.14107","article-title":"The Banff 2015 Kidney Meeting Report: Current challenges in rejection classification and prospects for adopting molecular pathology","volume":"17","author":"Loupy","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.02.110_bib11","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1681\/ASN.2016070797","article-title":"Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients","volume":"28","author":"Aubert","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2018.02.110_bib12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.kint.2017.03.033","article-title":"Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis","volume":"92","author":"Gosset","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2018.02.110_bib13","doi-asserted-by":"crossref","first-page":"e0178572","DOI":"10.1371\/journal.pone.0178572","article-title":"Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: results of an observational study","volume":"12","author":"Matignon","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.transproceed.2018.02.110_bib14","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1681\/ASN.2015080848","article-title":"Memory CD4 T cells induce antibody-mediated rejection of renal allografts","volume":"27","author":"Gorbacheva","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2018.02.110_bib15","doi-asserted-by":"crossref","first-page":"e12873","DOI":"10.1111\/petr.12873","article-title":"Bortezomib in the treatment of antibody-mediated rejection in pediatric kidney transplant recipients: a multicenter Midwest Pediatric Nephrology Consortium study","volume":"21","author":"Kizilbash","year":"2017","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.transproceed.2018.02.110_bib16","doi-asserted-by":"crossref","unstructured":"Ding Y, Francis J, Gautam A, Pelletier L, Sanchorawala V, Quillen K. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection. Clin Nephrol, in press.","DOI":"10.5414\/CN109278"},{"key":"10.1016\/j.transproceed.2018.02.110_bib17","doi-asserted-by":"crossref","first-page":"e13037","DOI":"10.1111\/ctr.13037","article-title":"Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab","volume":"31","author":"Mulley","year":"2017","journal-title":"Clin Transplant"},{"issue":"suppl 1","key":"10.1016\/j.transproceed.2018.02.110_bib18","first-page":"150","article-title":"Early versus late acute antibody-mediated rejection among renal transplant recipients in terms of response to rituximab therapy: a single center experience","volume":"15","author":"Gheith","year":"2017","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.transproceed.2018.02.110_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.trim.2014.08.005","article-title":"Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy","volume":"31","author":"Chung","year":"2014","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.transproceed.2018.02.110_bib20","unstructured":"Moreso F, Crespo M, Ruiz JC, Torres A, Gutierrez-Dalmau A, Osuna A, et\u00a0al. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial. Am J Transplant, in press."},{"issue":"suppl 1","key":"10.1016\/j.transproceed.2018.02.110_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5414\/CNP88FX21","article-title":"Treatment of antibody-mediated rejection of kidney grafts with bortezomib and\/or rituximab compared to standard regimen: experience of Slovene National Center","volume":"88","author":"Oblak","year":"2017","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.transproceed.2018.02.110_bib22","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1097\/TP.0000000000001617","article-title":"Treatment of acute antibody-mediated renal allograft rejection with cyclophosphamide","volume":"101","author":"Waiser","year":"2017","journal-title":"Transplantation"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134518302975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134518302975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T08:30:22Z","timestamp":1660638622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134518302975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0041134518302975"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.02.110","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Prolonged Treatment With Intravenous Immunoglobulin Infusions for Acute Antibody-mediated Rejection in Kidney Transplant Recipients","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.02.110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}